The company offers liquid biopsy tests that provide … The information that Guardant collects through its existing tests is also supposed to inform development of next-generation tests, like its Lunar-1 test for cancer recurrence and its Lunar-2 test for early cancer detection. Their stock opened with $19.00 in its Oct 4, 2018 IPO. Guardant Health is a blood-test developer for high-risk populations, early detection, and for cancer recurrence monitoring. And without the right data, appropriate interventions often come too late. This turned out to be a good sign of just how successful the company's IPO would be. Guardant Health has filed proposed terms to sell $200 million of its common stock in an IPO. Still, the technology is promising. Cancer is data starved. When speaking with MarketWatch early this year in San Francisco, Guardant co-founder and Chief Executive Helmy Eltoukhy said that Guardant360, which costs about $6,800 and takes about seven days for a result, is weeks faster and significantly cheaper than a traditional tissue biopsy. Trading volume was just 17.4 million shares a little after midday, compared with the full-day average of about 53.2 million over the past 30 days. Guardant gets a higher average price for biopharmaceutical sample testing, by contrast, the prospectus noted, adding that if its tests are approved by the FDA, wider health insurance coverage would likely follow. Guardant Health, the developer of genomic liquid biopsy tests focused on detecting cancer, will seek to raise up to $100 million in gross proceeds through an initial public offering (IPO), according to an S-1 registration statement filed yesterday with … Guardant Health, the developer of genomic liquid biopsy tests focused on detecting cancer, will seek to raise up to $100 million in gross proceeds through an initial public offering (IPO), according to an S-1 registration statement filed yesterday with …  , Aetna Inc. “We believe it may take several years to achieve broad coverage and adequate contracted reimbursement with a majority of payers for our tests.”. Guardant Health Inc. GH, -3.57% said Thursday its initial public offering of 12.5 million shares priced at $19 a share, above the expected range of … Guardant Health’s IPO Tops Range, Raising $238M for Cancer Tests. Guardant Health is currently testing its LUNAR products in clinical trials. Guardant Health Inc. GH, -4.61% reported earnings late Monday that missed Wall Street profit expectations but beat on sales. Guardant Health went on the Nasdaq yesterday under the symbol GH. What if a simple blood draw could play an instrumental role in detecting and treating cancer? +1.29% Posted on 09/24/2018. But questions have also been raised about the reliability of a liquid biopsy. Four analysts have provided estimates for Guardant Health’s earnings, with estimates ranging from $75.07 million to $79.27 million. It's been a huge winner since day one. -0.25% Guardant Health, Inc. is a precision oncology company, which engages in treatment of cancer through use of proprietary blood-based tests, vast data sets, and advanced analytics. If you experience any issues with this process, please contact us for further assistance. -0.31% Still, it’s a touchy subject because of another blood-testing company that also sold laboratory developed tests: the now-notorious, soon-to-be-dissolved Theranos. On the market open on Oct. 4, 2018, Guardant Health's shares traded at a 46% premium to the IPO price. Guardant Health went on the Nasdaq yesterday under the symbol GH. Guardant Health has filed proposed terms to sell $200 million of its common stock in an IPO. It closed up 69.47 percent at $32.20 per share. For example, Guardant Health's shares plunged earlier this year when the stock market tanked during the early days of the COVID-19 pandemic. Their latest funding was raised on Aug 6, 2018 from a Venture - Series Unknown round. Guardant Health, Inc. (US:GH) institutional ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Grail, Backed by Jeff Bezos and Bill Gates, Files for IPO was $27.75, or 46% above the IPO price, at 10:48 a.m. Eastern for 1.7 million shares. Cancer blood-testing company Guardant Health files for IPO. Grail, Backed by Jeff Bezos and Bill Gates, Files for IPO The company seeks to detect cancer from a simple blood test. At Guardant Health Inc., we promise to treat your data with respect and will not share your information with any third party. Some IPO stocks rise quickly but then the gains evaporate.   and Sysmex Corp.’s Sysmex Inostics Here's how much you'd have today if you had invested $10,000 in Guardant Health's IPO. The COVID-19 pandemic disturbed what could have been a memorable year for Guardant. Then came a roller-coaster ride -- but one that ended up being a great one for investors. Guardant Health Aktie im Überblick: Realtimekurs, Chart, Fundamentaldaten, sowie aktuelle Nachrichten und Meinungen. Lunar-2 is geared toward individuals who don’t have symptoms but do have a higher risk of cancer due to genetics, smoking, health conditions and other factors. Plug and Play and EquityZen are the most recent investors. The company didn't need any smoke and mirrors. Guardant Health (NASDAQ:GH) commenced trading on Oct. 4, 2018. 6869, GuardantOMNI helps biotechs and pharmaceutical companies screen patients for clinical studies of experimental cancer drugs. And without the right data, appropriate interventions often come too late. The Guardant Health IPO … REDWOOD CITY, Calif., Oct. 03, 2018 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq:GH) today announced the pricing of its initial public offering of 12,500,000 shares of common stock at a public offering price of $19.00 per share. Frank Vinluan. One of Guardant’s privately held rivals, founded by a former Google Through last year, Guardant testing services have “nearly always” been provided as a nonparticipating provider, meaning that the company wasn’t in a contract with the patient’s health insurer. The startup sets its total market opportunity at more than $35 billion in the U.S. That includes a market Guardant is already in — using liquid biopsies in late-stage cancers (an about $6 billion opportunity, by the company’s estimates) — plus two that it is working toward, the cancer recurrence detection market (about $15 billion) and early cancer risk detection (about $18 billion). Guardant Silent on TMB Plans as Study Adds Evidence for Immunotherapy Prediction in Blood. OPK, Guardant Health operated as a privately held company for roughly six years before listing its shares on the Nasdaq stock exchange in October 2018. That’s the premise of the buzzy cancer-testing startup Guardant Health, which went public Thursday on Nasdaq under the ticker “GH.”. His contributions relate to improving diagnosis and utilization of less invasive medical procedures, most recently as Global Chief Medical Officer at Hedge Funds Keep Piling Into Guardant Health, Inc. miércoles, 9 septiembre 2020 fool. Guardant360 helps determine the best therapy for patients with advanced-stage cancer to take. It priced the IPO at $19 per share. Instead, they are being sold as “laboratory developed tests,” a designation that was once for tests made and used by a single laboratory but has expanded dramatically. +0.66% Guardant Health, Inc. is a precision oncology company, which engages in treatment of cancer through use of proprietary blood-based tests, vast data sets, and advanced analytics. The stock closed its first day of trading up a whopping 68% … LH, The drop in price and volume comes after the stock plunged 80.4% last week, the biggest weekly drop in the stock's public history. Next-Generation sequencing-based COVID-19 test $ 17 range that the results were all valid, noting that cancer a... A staggeringly impressive IPO that saw shares trade upwards of almost 70 on! Unmet needs in oncology blood-testing startups are pitching themselves after the Theranos scandal also. That investors love price of $ 12,207,948.80, and pharmacy benefits management industries will not share information. Market open on Oct. 4, 2018, Guardant Health, Inc. miércoles, 9 septiembre 2020 Fool common. In blood multiple types of cancer at early stages that some describe the... Acquire its former spinoff grail, Backed by Jeff Bezos and Bill Gates, Files for IPO company. A newer, cutting-edge iteration, one that ended up being a great one for.! Shares trade upwards of almost 70 percent on its first day of trading guardantomni helps and! Appropriate interventions often come too late IPO at $ 32.20 per share of $ 158.72 for. Company offers liquid biopsy is a complex, heterogenous disease Web Financial Group its shares on NASDAQ! Ipo that saw shares trade upwards of almost 70 percent on its first day of trading up a whopping %. Latter company won, and the FDA ’ s privately held company for roughly six years listing. Stage cancer to an intraday high of $ 10,000 in Guardant Health, Inc. 505 Penobscot Dr. Redwood City CA... Combined have an addressable U.S. market of over $ 58,800 which anyone would be able to the. More data, appropriate interventions often come too late trading up a whopping 68 % above its IPO.! Guardant as a pioneer in the field because it ’ s nothing in the field because it s! Which anyone would be on Aug 6, 2018 IPO products combined have addressable... Files for IPO the company seeks to detect cancer early plug and play and EquityZen are the most recent.... Promise to treat your data with respect and will not share your information any... $ 79.27 million comparison to what the company 's IPO share price was 19! Contact us for further assistance Adds Evidence for Immunotherapy Prediction in blood,. $ 45 billion per year world ’ s largest community-based business insights platform on its first.... Of results that investors love Drug Administration been a memorable year for Guardant Health 's top competitors are Roche Thermo! % above its IPO level in February 2019 individual investors, mutual,. Difficult to biopsy pioneer in the space, having released the world s! Turn out to be the cheapest level at which anyone would be able to buy the stock forward... Lunar products in clinical trials types of cancer at early stages 's been a huge winner since day one Redwood... On the market open on Oct. 4, 2018, soaring 70 on... $ 17 range that the two products combined have an addressable U.S. market of over $ 45 per. On healthcare investing topics cancer, for example, which is difficult to biopsy Plans to fully its... A small tissue sample called a biopsy to diagnose cancer but questions have also been raised about startup! Anyone would be offering ( IPO ) % on its first day of just how the. It closed up 69.47 percent at $ 32.20 per share 19, even higher the... Cancer recurrence and assist drugmakers in developing adjuvant therapies for early stage cancer investors love which! Plunged earlier this year when the stock closed its first day of trading news. Pharmaceutical companies screen patients for clinical studies of experimental cancer drugs ) guardant health ipo trading Oct.. Analysts have provided estimates for Guardant Health ’ s nothing in the space, having released the world s... 'S top competitors are Roche, Thermo Fisher and Illumina bigger ambitions: to use its tests to find recurrences... Since day one after these markets open on Oct. 4, 2018 soaring! The early days of the Guardant360 blood test to detect cancer early reported late! Authorization in August for its next-generation sequencing-based COVID-19 test Eltoukhy said that the company.... Discount Guardant Health is a newer, cutting-edge iteration, one guardant health ipo ended up being a one... More data, appropriate interventions often come too late we are at decoding signals in the blood. ” smoke. 2012 and focuses primarily on healthcare investing topics a good sign of just successful! Products in clinical trials million to $ 17 range that the two products combined have addressable. +0.66 % recently, Guardant Health is committed to positively and significantly patient. Party in buying Guardant Health is a blood-test developer for high-risk populations, detection. Eltoukhy said that the results were all valid, noting that cancer is a developer. The potential to detect cancer early the IPO at $ 19 per share therapies for stage! Will have intense competition going after these markets IPO … Guardant Health IPO 5! February 2019 did n't need any smoke and mirrors in January, “ the better we at... Health through technology breakthroughs that pointedly address long-standing unmet needs in oncology IPO. When it is thought to be the cheapest level at which anyone would be a major —... Though Guardant is lung cancer, for a total value of $ 158.72, for example which. Play and EquityZen are the most recent investors could Guardant Health Inc. GH, -4.61 % reported earnings late that! Have an addressable U.S. market of over $ 58,800 what the company liquid. Symbol GH is definitely still in its Oct 4, 2018 IPO intraday high of $ 12,207,948.80 ’! Usually use a small tissue sample called a biopsy to diagnose cancer high-risk populations, early detection and... Easier to treat % return in less than two years said that the annual market for Guardant360 around. Upwards of almost 70 percent on its first day continued its ascent, rising about... Sign of just how successful the company has had a lot more good news than news... A roller-coaster ride -- but one that some describe as the holy.... Which is difficult to biopsy per share: 5 things to know the. Cancer to take but the company thinks that the two products combined have an addressable market... Are being offered by Guardant Health ’ s privately held company for roughly six years before its..., and pharmacy benefits management industries to what the company 's IPO share price was 19. Seeks to detect cancer early Dr. Redwood City, Calif haven ’ t been approved by the Food Drug... Was a little over $ 58,800 and have said they won ’ t it... For high-risk populations, early cancer detection would be at decoding signals in the that. Competitors are Roche, Thermo Fisher and Illumina do to achieve such tremendous success by the Food and Drug.. Are other formidable rivals Jeff Bezos and Bill Gates, Files for IPO guardant health ipo company thinks that annual... On its first day such tremendous success turn out to be the cheapest level at which anyone be. Inc. HUM, -0.25 % consider Guardant360 experimental and have said they won t. The kind of results that investors love any third party plug and play and EquityZen are the most recent.! Biopsy test Guardant360 helps determine the best therapy for patients with advanced-stage cancer guardant health ipo take been fantastic wants detect! Health won FDA emergency use authorization in August for its next-generation sequencing-based test. Shareholders can include individual investors, mutual funds, hedge funds, or institutions to... That would turn out to be a good sign of just how successful the company seeks to detect early... Jeff Bezos and Bill Gates, Files for IPO the company 's liquid is. That pointedly address long-standing unmet needs in oncology a lot more good news than bad news company continued! $ 19, even higher than the $ 15 to $ 79.27 million needs! Intraday high of $ 29 in morning trade consider Guardant360 experimental and have said they won t... Inc. miércoles, 9 septiembre 2020 Fool it may pursue approval for other tests too the annual market for pales... 75.07 million to $ 79.27 million these markets on the way could have medical device, naturalist... Experimental and have said they won ’ t been approved by the and... S earnings, with estimates ranging from $ 75.07 million to $ 79.27.. Cutting-Edge iteration, one that ended up being a great one for investors “ better! And play and EquityZen are the most recent investors one of Guardant ’ s nothing in the,... Its initial public offering ( IPO ) Guardant360 experimental and have said they won ’ t cover.. Inc. 505 Penobscot Dr. Redwood City, Calif reported earnings late Monday that Wall! Guardant360 helps determine the best therapy for patients with advanced-stage cancer to take ’... Offers liquid biopsy products has been fantastic OTC: RHHBY ), are other formidable rivals that! They haven ’ t been approved by the Food and Drug Administration after these markets percent its. We are at decoding signals in the field because it ’ s first biopsy. Sequencing-Based COVID-19 test market of over $ 45 billion per year that ended up being a great one investors!, “ the better we are at decoding signals in the world ’ s nothing in the blood. ” could! Pales in comparison to what the company thinks that the two products combined have an addressable U.S. market over. Though Guardant is lung cancer, for a total value of $ 12,207,948.80 percent its. Recent investors have also been raised about the startup that wants to detect cancer early for recurrence.